Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ZBH 
Zimmer Biomet Holdings Inc (ZBH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: ZBH (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
29 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $110.92
1 Year Target Price $110.92
| 5 | Strong Buy |
| 6 | Buy |
| 16 | Hold |
| 1 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -34.68% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 20.23B USD | Price to earnings Ratio 24.91 | 1Y Target Price 110.92 |
Price to earnings Ratio 24.91 | 1Y Target Price 110.92 | ||
Volume (30-day avg) 29 | Beta 0.68 | 52 Weeks Range 88.99 - 115.64 | Updated Date 08/15/2025 |
52 Weeks Range 88.99 - 115.64 | Updated Date 08/15/2025 | ||
Dividends yield (FY) 0.93% | Basic EPS (TTM) 4.1 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-05 | When Before Market | Estimate 1.98 | Actual 2.07 |
Profitability
Profit Margin 10.51% | Operating Margin (TTM) 19.52% |
Management Effectiveness
Return on Assets (TTM) 4.36% | Return on Equity (TTM) 6.53% |
Valuation
Trailing PE 24.91 | Forward PE 12.8 | Enterprise Value 27245161886 | Price to Sales(TTM) 2.58 |
Enterprise Value 27245161886 | Price to Sales(TTM) 2.58 | ||
Enterprise Value to Revenue 3.48 | Enterprise Value to EBITDA 11.97 | Shares Outstanding 198096000 | Shares Floating 197497734 |
Shares Outstanding 198096000 | Shares Floating 197497734 | ||
Percent Insiders 0.15 | Percent Institutions 101.67 |
Upturn AI SWOT
Zimmer Biomet Holdings Inc
Company Overview
History and Background
Zimmer Biomet Holdings, Inc. was founded in 1927 as Zimmer Manufacturing Company. Initially focused on aluminum splints, it evolved into a leading global medical technology company. In 2015, Zimmer merged with Biomet, creating a larger, diversified organization. The company's history is marked by innovation in orthopedics and strategic acquisitions.
Core Business Areas
- Knees: Designs, manufactures, and markets knee replacement implants and related surgical products and services.
- Hips: Offers hip replacement implants and related surgical products and services, focusing on various surgical approaches.
- S.E.T. (Sports Medicine, Extremities, Trauma, and Biologics): Includes sports medicine, upper and lower extremities, trauma, and biologics products, providing solutions for soft tissue repair, fracture management, and bone healing.
- Dental: Develops and markets dental reconstructive products, including dental implants, abutments, and regenerative materials.
- Spine: Offers spinal implants, instruments, and biologics used in spinal fusion and other spinal procedures.
Leadership and Structure
The CEO of Zimmer Biomet is Ivan Tornos. The company operates with a global organizational structure, divided into geographical regions (Americas, EMEA, Asia Pacific) and product-focused business units. Board includes independent directors with diverse expertise.
Top Products and Market Share
Key Offerings
- Persona Knee System: A personalized knee replacement system designed to match patient anatomy. Competitors include Stryker's Triathlon and Johnson & Johnson's Attune Knee Systems. Market share is significant but varies geographically. Revenue information for specific products is not publicly broken down in detail, but Knee reconstruction represents a significant portion of overall revenue.
- G7 Acetabular System: A hip implant system designed for stability and longevity. Competitors include Smith & Nephew's R3 and DePuy Synthes' Pinnacle systems. Similar to the Persona Knee System, the market share is substantial but varies based on region. Hip reconstruction also represents a considerable portion of total revenue.
- Comprehensive Reverse Shoulder System: A reverse shoulder arthroplasty system for patients with rotator cuff deficiency. Competitors include Exactech and DJO Global. Shoulder replacement is a smaller but growing market segment.
- Taperloc Complete Hip System: A cementless hip implant designed for stability. Competitors include Stryker's Accolade II and DePuy Synthes' ACTIS systems. Taperloc Complete Hip System aims to provide a stable platform to support a range of patients.
Market Dynamics
Industry Overview
The orthopedic market is driven by an aging population, increasing prevalence of arthritis and osteoporosis, and advancements in surgical techniques and implant technology. It's a competitive landscape with significant consolidation.
Positioning
Zimmer Biomet is a leading player in the orthopedic market, with a broad product portfolio and global presence. Its competitive advantage lies in its established brand, extensive distribution network, and commitment to innovation.
Total Addressable Market (TAM)
The global orthopedic market is projected to reach hundreds of billions of dollars. Zimmer Biomet is well-positioned to capture a significant share of this market, given its scale and product offerings.
Upturn SWOT Analysis
Strengths
- Broad product portfolio
- Global presence and distribution network
- Strong brand recognition
- Extensive research and development capabilities
- Strong relationships with surgeons and hospitals
Weaknesses
- Integration challenges following the Zimmer-Biomet merger
- Exposure to pricing pressures from healthcare providers
- Product recalls and quality control issues
- High debt levels
Opportunities
- Expanding into emerging markets
- Developing new and innovative orthopedic technologies
- Acquiring complementary businesses
- Leveraging data analytics and digital technologies
- Capitalizing on the growing demand for minimally invasive surgical procedures
Threats
- Intense competition from other orthopedic companies
- Regulatory changes and increased scrutiny of medical devices
- Economic downturns and reduced healthcare spending
- Product liability lawsuits
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- JNJ
- SYK
- SMITH
Competitive Landscape
Zimmer Biomet operates in a highly competitive market. Its advantages include a broad product portfolio and global scale. Disadvantages may include integration challenges and exposure to pricing pressures.
Major Acquisitions
Medtronic Spine division
- Year: 2022
- Acquisition Price (USD millions): 3700
- Strategic Rationale: Significantly expand Zimmer Biomet's spine business, offering a more comprehensive portfolio of spine products and technologies.
Relign Technologies
- Year: 2023
- Acquisition Price (USD millions): 170
- Strategic Rationale: Adding image guided surgery capabilities and robotic assistance to existing portfolio
Growth Trajectory and Initiatives
Historical Growth: Growth has been a combination of organic expansion and acquisitions. The merger with Biomet significantly expanded the company's reach.
Future Projections: Analyst estimates suggest moderate revenue growth driven by new product launches, market expansion, and favorable demographics.
Recent Initiatives: Recent initiatives include investments in R&D, strategic acquisitions, and efforts to improve operational efficiency and supply chain resilience.
Summary
Zimmer Biomet is a leading orthopedic company with a strong market position and a diverse product portfolio. While the company faces integration challenges and competitive pressures, it is poised for growth through innovation, market expansion, and strategic acquisitions. Maintaining focus on operational efficiencies and quality control is crucial to realizing its potential and delivering value to shareholders. The recent acquisitions shows that the company is improving its technology and revenue pipeline.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Zimmer Biomet Investor Relations
- SEC Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
This analysis is based on available information and is not financial advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Zimmer Biomet Holdings Inc
Exchange NYSE | Headquaters Warsaw, IN, United States | ||
IPO Launch date 2001-07-25 | President, CEO & Chairman of the Board Mr. Ivan Tornos | ||
Sector Healthcare | Industry Medical Devices | Full time employees 17000 | Website https://www.zimmerbiomet.com |
Full time employees 17000 | Website https://www.zimmerbiomet.com | ||
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.